Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control

Tempest Therapeutics, Inc.

2023-Q2 EPS reported -$1.09

Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.
Net loss Q2 2023 $7.6M ($0.54/share) vs $9.2M ($0.79/share) in Q2 2022.
TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% (5/29) for control; confirmed ORR 17.5% vs 10.3%.
47.5% of TPST-1120 arm patients on treatment vs 23.3% in control; 80% on study vs 50%.
Expect to discuss updated TPST-1120 data from formal review in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, EPS $0.54.

Period: the quarter ended June 30, 2023
Net income: Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively
EPS: $0.54
Result: reported results

Exact text from the filing

Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, compared to $9.2 million and $0.79, respectively, for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the six months ended June 30, 2023 results: net income Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, EPS $1.09.

Period: the six months ended June 30, 2023
Net income: Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively
EPS: $1.09
Result: reported results

Exact text from the filing

Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, compared to $17.7 million and $1.88, respectively, for the same period in 2022.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041385

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.